GlassScriptPhysician profile
Annalisa M Cochran
NPI 1144623422
$2,045.01
in general payments reported to CMS, 2019-2025
18 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $656 · 2023: $863 · 2024: $68.75 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913 · Travel and Lodging: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.23 |
| Travel and Lodging | $245.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $881.76 | 2023-2025 | Watchman Access System, General - Ep, Farapulse |
| Novartis Pharmaceuticals Corporation | $288.48 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $141.96 | 2021-2022 | |
| Itamar Medical INC | $127.53 | 2023-2025 | Watchpatone |
| Pfizer INC. | $125.78 | 2021-2022 | |
| Atricure, INC. | $96.29 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.89 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.83 | 2022 | |
| Impulse Dynamics (USA) INC. | $45.07 | 2024 | Optimizer |
| Merck Sharp & Dohme LLC | $41.79 | 2022 | |
| Philips North America LLC | $41.52 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $35.64 | 2021-2022 | |
| Novo Nordisk INC | $30.12 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.17 | 2021-2022 | |
| Esperion Therapeutics, INC. | $21.38 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $14.19 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.41 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annalisa Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.